Source: http://www.asmscience.org/content/book/10.1128/9781555816728.chap69
Timestamp: 2019-04-23 20:06:26+00:00

Document:
Commercial antimicrobial susceptibility testing (AST) systems were introduced into clinical microbiology laboratories during the 1980s and have been used in the majority of laboratories since the 1990s. Manual and semiautomated broth microdilution systems are utilized for small volumes of susceptibility testing, while larger laboratories often choose an automated broth microdilution system. The AST systems include data management software that may be interfaced with a laboratory information system (LIS) and offer various levels of expert system and epidemiological analyses. This chapter focuses primarily on commercial susceptibility testing systems currently available in the United States. It discusses advantages and disadvantages of automated systems. Reports of AST performance for detecting problematic resistance phenotypes are also discussed. Expert systems to assist in the critical review of AST results are available for all commercial susceptibility systems currently marketed in the United States. Most expert systems use a rules-based approach focusing on AST results for one drug at a time without considering results for other agents tested simultaneously. Factors to consider when selecting an AST system include cost, performance, work flow, data management capabilities, and manufacturer technical support. Future advances in the development of AST systems may increase their clinical impact with the incorporation of molecular techniques that dramatically shorten the time required for results.
1. Andrew, J. M.,, F. J. Boswell,, and R. Wise. 2000. Evaluation of the Oxoid Aura image system for measuring zones of inhibition with the disc diffusion technique. J. Antimicrob. Chemother. 46: 535– 540.
2. Barenfanger, J.,, C. Drake,, and G. Kacich. 1999. Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. J. Clin. Microbiol. 37: 1415– 1418.
3. Barry, J.,, A. Brown,, V. Ensor,, U. Lakhani,, D. Petts,, C. Warren,, and T. Winstanley. 2003. Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J. Antimicrob. Chemother. 51: 1191– 1202.
4. Berke, I.,, and P. M. Tierno, Jr. 1996. Comparison of efficacy and cost-effectiveness of BIOMIC VIDEO and VITEK antimicrobial susceptibility test systems for use in the clinical microbiology laboratory. J. Clin. Microbiol. 34: 1980– 1984.
5. Bert, F.,, M. Juvin,, Z. Ould-Hocine,, G. Clarebout,, E. Keller,, N. Lambert,, and G. Arlet. 2005. Evaluation and updating of the Osiris expert system for identification of Escherichia coli b-lactam resistance phenotypes. J. Clin. Microbiol. 43: 1846– 1850.
6. Bert, F.,, Z. Ould-Hocine,, M. Juvin,, V. Dubois,, V. Loncle-Provot,, V. LeFranc,, C. Quentin,, N. Lambert,, and G. Arlet. 2003. Evaluation of the Osiris expert system for identification of β-lactam phenotypes in isolates of Pseudomonas aeruginosa. J. Clin. Microbiol. 41: 3712– 3718.
7. Blondel-Hill, E.,, C. Hetchler,, D. Andrews,, and L. Lapointe. 2003. Evaluation of VITEK 2 for analysis of Enterobacteriaceae using the Advanced Expert System (AES) versus interpretive susceptibility guidelines used at Dynacare Kasper Medical Laboratories, Edmonton, Alberta. Clin. Microbiol. Infect. 9: 1091– 1103.
8. Bratu, S.,, D. Landman,, R. Haag,, R. Recco,, A. Eramo,, M. Alam,, and J. Quale. 2005. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City. Arch. Intern. Med. 165: 1430– 1435.
9. Brigante, G. R.,, F. A. Luzzaro,, B. Pini,, G. Lombardi,, G. Sokeng,, and A. Q. Toniolo. 2007. Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system. BMC Microbiol. 7: 46– 52.
10. Burns, J. L.,, L. Saiman,, S. Whittier,, J. Krzewinski,, Z. Liu,, D. Larone,, S. A. Marshall,, and R. N. Jones. 2001. Comparison of two commercial systems (VITEK and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 39: 257– 260.
11. Carroll, K. C.,, A. P. Borek,, C. Burger,, B. Glanz,, H. Bhally,, S. Henciak,, and S. C. Flayhart. 2006. Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of staphylococci and enterococci. J. Clin. Microbiol. 44: 2072– 2077.
12. Centers for Disease Control and Prevention. 2004. Vancomycin-resistant Staphylococcus aureus—New York, 2004. MMWR Morb. Mortal. Wkly. Rep. 53: 322– 323.
13. Chapin, K. C.,, and M. C. Musgnug. 2003. Validation of the automated reading and incubation system with Sensititre plates for antimicrobial susceptibility testing. J. Clin. Microbiol. 41: 1951– 1956.
14. Chapin, K. C.,, and M. C. Musgnug. 2004. Evaluation of Sensititre automated system for automated reading of Sensititre broth microdilution susceptibility plates. J. Clin. Microbiol. 42: 909– 911.
15. Chen, H. M.,, J. J. Wu,, P. F. Tsai,, J. Y. Wann,, and J. J. Yan. 2009. Evaluation of the capability of the VITEK 2 system to detect extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumonia isolates, in particular with the coproduction of AmpC enzymes. Eur. J. Clin. Microbiol. Infect. Dis. 28: 871– 874.
16. Chen, Y.-S.,, S. A. Marshall,, P. L. Winokur,, S. L. Coffman,, W.W. Wilkie,, P. R. Murray,, C. A. Spiegel,, M. A. Pfaller,, G. V. Doern,, and R. N. Jones. 1998. Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. J. Clin. Microbiol. 36: 2996– 3001.
17. Clinical and Laboratory Standards Institute. 2008. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters, Approved Guideline M23-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2009. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria That Grow Aerobically, Approved Standard M07-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2010. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
20. d’Azevedo, P. A.,, C. A.G. Dias,, A. L. S. Goncalves,, F. Rowe,, and L. M. Teixeira. 2001. Evaluation of an automated system for the identification and antimicrobial susceptibility testing of enterococci. Diagn. Microbiol. Infect. Dis. 40: 157– 161.
21. Del’Alamo, L.,, R. F. Cereda,, I. Tosin,, E. A. Miranda,, and H. S. Sader. 1999. Antimicrobial susceptibility of coagulasenegative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn. Microbiol. Infect. Dis. 34: 185– 191.
22. Doern, G. V.,, R. Vautour,, M. Gaudet,, and B. Levy. 1994. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J. Clin. Microbiol. 32: 1757– 1762.
23. Donaldson, H.,, M. McCalmont,, D. M. Livermore,, P. J. Rooney,, G. Ong,, E. McHenry,, R. Campbell,, and R. McMullan. 2008. Evaluation for the VITEK 2 AST N-054 test card for the detection of extended-spectrum b-lactamase production in Escherichia coli with CTX-M phenotypes. J. Antimicrob. Chemother. 62: 1015– 1017.
24. Donay, J.-L.,, D. Mathieu,, P. Fernandes,, C. Pregermain,, P. Bruel,, A. Wargnier,, I. Casin,, F. X. Weill,, P. H. Lagrange,, and J. L. Herrmann. 2004. Evaluation of the automated Phoenix system for potential routine use in the clinical microbiology laboratory. J. Clin. Microbiol. 42: 1542– 1546.
25. Eigner, U.,, A. Schmid,, U. Wild,, D. Bertsch,, and A.-M. Fahr. 2005. Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems . J. Clin. Microbiol. 43: 3829– 3834.
26. Endimiani, A.,, F. Luzzaro,, A. Tamborini,, G. Lombardi,, V. Elia,, R. Belloni,, and A. Toniolo. 2002. Identification and antimicrobial susceptibility testing of clinical isolates of nonfermenting gram-negative bacteria by the Phoenix automated microbiology system. Microbiologica 25: 323– 329.
27. Fahr, A. M.,, U. Eigner,, M. Armbrust,, A. Caganic,, G. Dettori,, C. Chezzi,, L. Bertoncini,, M. Benecchi,, and M. G. Menozzi. 2003. Two-center collaborative evaluation of the performance of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterococcus spp. and Staphylococcus spp . J. Clin. Microbiol. 41: 1135– 1142.
28. Federal Register. 1992. Clinical Laboratory Improvement Amendments of 1988; final rule. Fed. Regist. 57: 7164.
29. Felten, A.,, B. Grandry,, P. H. Lagrange,, and I. Casin. 2002. Evaluation of three techniques for detection of low-level methicillin-resistant Staphylococcus aureus (MRSA): a diskdiffusion method with cefoxitin and moxalactam, the VITEK 2 system, and the MRSA-screen latex agglutination test. J. Clin. Microbiol. 40: 2766– 2771.
30. Food and Drug Administration. 2003. Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices. 21 CFR 807. Food and Drug Administration, Rockville, MD.
31. Food and Drug Administration. June 2009. Guidance for Industry: Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices. Food and Drug Administration, Rockville, MD.
32. Food and Drug Administration. 28 August 2009. Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Food and Drug Administration, Rockville, MD.
33. Garcia-Garrote, F.,, E. Cercenado,, and E. Bouza. 2000. Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J. Clin. Microbiol. 38: 2108– 2111.
34. Geiss, H. K.,, and U. E. Klar. 2000. Evaluation of the BIOMIC video reader system for routine use in the clinical microbiology laboratory. Diagn. Microbiol. Infect. Dis. 37: 151– 155.
35. Goessens, W. H. F.,, N. Lemmens-den Toom,, J. Hageman,, P. W. M. Hermans,, M. Sluijter,, R. de Groot,, and H. A. Verbrugh. 2000. Evaluation of the VITEK 2 system for susceptibility testing of Streptococcus pneumoniae isolates. Eur. J. Clin. Microbiol. Infect. Dis. 19: 618– 622.
35a. Gosnell, C.,, C. Yu,, D. Turner,, and J. Reuben. 2008. 18th Eur. Congr. Clin. Microbiol. Infect. Dis., abstr. P854.
36. Guthrie, L. L.,, S. Banks,, W. Setiawan,, and K. B. Waites. 1999. Comparison of MicroScan MICroSTREP, Pasco, and Sensititre MIC panels for determining antimicrobial susceptibilities of Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 33: 267– 273.
37. Horstkotte, M. A.,, J. K.-M. Knobloch,, H. Rohde,, S. Dobinsky,, and D. Mack. 2002. Rapid detection of methicillin resistance in coagulase-negative staphylococci with the VITEK 2 system. J. Clin. Microbiol. 40: 3291– 3295.
38. Horstkotte, M. A.,, J. K.-M. Knobloch,, H. Rohde,, S. Dobinsky,, and D. Mack. 2004. Evaluation of the BD PHOENIX automated system for detection of methicillin resistance in coagulase-negative staphylococci. J. Clin Microbiol. 42: 5041– 5046.
39. Hussain, Z.,, L. Stoakes,, M. A. John,, S. Garrow,, and V. Fitzgerald. 2002. Detection of methicillin resistance in primary blood culture isolates of coagulase-negative staphylococci by PCR, slide agglutination, disk diffusion, and a commercial method. J. Clin. Microbiol. 40: 2251– 2253.
40. Hussain, Z.,, L. Stoakes,, V. Massey,, D. Diagre,, V. Fitzgerald,, S. El Sayed,, and R. Lannigan. 2000. Correlation of oxacillin MIC with mecA gene carriage in coagulase-negative staphylococci. J. Clin. Microbiol. 38: 752– 754.
41. John, M. A.,, J. Burden,, J. I. Stuart,, R. C. Reyes,, R. Lannigan,, S. Milburn,, D. Diagre,, B. Wilson,, and Z. Hussain. 2009. Comparison of three phenotypic techniques for detection of methicillin resistance in Staphylococcus spp. Reveals a species-dependent performance. J. Antimicrob. Chemother. 63: 493– 496.
42. Jones, R. N. 2001. Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of American Pathologists Microbiology Survey Program ( 2000 ). Arch. Pathol. Lab. Med. 125: 1285– 1289.
43. Jorgensen, J. H. 1993. Selection criteria for an antimicrobial susceptibility testing system. J. Clin. Microbiol. 31: 2841– 2844.
44. Jorgensen, J. H.,, A. L. Barry,, M. M. Traczewski,, D. F. Sahm,, M. L. McElmeel,, and S. A. Crawford. 2000. Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2. J. Clin. Microbiol. 38: 2814– 2818.
45. Jorgensen, J. H.,, and M. J. Ferraro. 2009. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin. Infect. Dis. 49: 1749– 1755.
46. Jorgensen, J. H.,, and M. J. Ferraro. 2000. Antimicrobial susceptibility testing: special needs for fastidious organisms and difficult-to-detect resistance mechanisms. Clin. Infect. Dis. 30: 799– 808.
47. Jorgensen, J. H.,, S. A. Crawford,, L. M. McElmeel,, and C. G. Whitney. 2004. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument. J. Clin. Microbiol. 42: 5928– 5930.
48. Jorgensen, J. H.,, S. A. Crawford,, M. L. McElmeel,, and K. R. Fiebelkorn. 2004. Detection of inducible clindamycin resistance in conjunction with performance of automated broth susceptibility testing. J. Clin. Microbiol. 42: 1800– 1802.
49. Joyanes, P.,, M. D. C. Conejo,, L. Martinez-Martinez,, and E. J. Perea. 2001. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J. Clin. Microbiol. 39: 3247– 3253.
50. Junkins, A. D.,, S. R. Lockhart,, K. P. Heilmann,, C. L. Dohrn,, D. L. Von Stein,, P. L. Winokur,, G. V. Doern,, and S. S. Richter. 2009. BD Phoenix and Vitek 2 detection of mecA-mediated resistance in Staphylococcus aureus with cefoxitin. J. Clin. Microbiol. 47: 2879– 2882.
50a. Junkins, A. D.,, S. S. Arbefeville,, W. J. Howard,, and S. S. Richter. 2010. Comparison of BD Phoenix AP workflow with Vitek 2. J. Clin. Microbiol. 48: 1929– 1931.
51. Juretschko, S.,, V. J. LaBombardi,, S. A. Lerner,, P. C. Schreckenberger, and the Pseudomonas AST Study Group. 2007. Accuracies of b-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J. Clin. Microbiol. 45: 1339– 1342.
52. Kaase, M.,, B. Baars,, S. Friedrich,, F. Szabados,, and S. G. Gatermann. 2009. Performance of MicroScan WalkAway and VITEK 2 for detection of oxacillin resistance in a set of methicillin-resistant Staphylococcus aureus isolates with diverse genetic backgrounds. J. Clin. Microbiol. 47: 2623– 2625.
53. Kaase, M.,, S. Lena,, S. Friedrich,, F. Szabados,, T. Sakinc,, B. Kleine,, and S. G. Gatermann. 2008. Comparison of phenotypic methods for penicillinase detection in Staphylococcus aureus. Clin. Microbiol. Infect. 14: 614– 616.
54. Karlowsky, J. A.,, M. K. Weaver,, C. Thornsberry,, M. J. Dowzicky,, M. E. Jones,, and D. F. Sahm. 2003. Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillintazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 41: 3339– 3343.
55. Kolbert, M.,, F. Chegrani,, and P. M. Shah. 2004. Evaluation of the OSIRIS video reader as an automated measurement system for the agar disk diffusion technique. Clin. Microbiol. Infect. 10: 416– 420.
56. Komatsu, M.,, M. Aihara,, K. Shimakawa,, M. Iwasaki,, Y. Nagasaka,, S. Fukuda,, S. Matsuo,, and Y. Iwatani. 2003. Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae-producing, extended-spectrum b-lactamases isolated in Japan. Diagn. Microbiol. Infect. Dis. 46: 125– 130.
57. Korgenski, E. K.,, and J. A. Daly. 1998. Evaluation of the BIOMIC video reader system for determining interpretive categories of isolates on the basis of disk diffusion susceptibility results. J. Clin. Microbiol. 36: 302– 304.
58. Kulah, C.,, E. Aktas,, F. Comert,, N. Ozlu,, I. Akyar,, and H. Ankarali. 2009. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, MicroScan WalkAway, Vitek 2); high error rates with MicroScan WalkAway. BMC Infect. Dis. 9: 30– 37.
58a.. LeClercq, R.,, A. Boulanger,, F. Doucet-Populaire,, S. Galopin,, M. Ploy,, and C. Poyart. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. D-797.
59. Lestari, E. S.,, J. A. Severin,, P. M. G. Filius,, K. Kuntaman,, D. O. Duerink,, U. Hadi,, H. Wahjono,, and H. A. Verbrugh. 2008. Comparison of the accuracy of disk diffusion zone diameters obtained by manual zone measurements to that by automated zone measurements to determine antimicrobial susceptibility. J. Microbiol. Methods 75: 177– 181.
60. Leverstein-van Hall, M.,, A. C. Fluit,, A. Paauw,, A. T. A. Box,, S. Brisse,, and J. Verhoef. 2002. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. J. Clin. Microbiol. 40: 3703– 3711.
61. Ligozzi, M.,, C. Bernini,, M. G. Bonora,, M. de Fatima,, J. Zuliani,, and R. Fontana. 2002. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. J. Clin. Microbiol. 40: 1681– 1686.
62. Linscott, A. J.,, and W. J. Brown. 2005. Evaluation of four commercially available extended-spectrum beta-lactamase phenotypic confirmation tests. J. Clin. Microbiol. 43: 1081– 1085.
63. Livermore, D. M.,, M. Struelens,, J. Amorin,, F. Baquero,, J. Bille,, R. Canton,, S. Henning,, S. Gatermann,, A. Marchese,, H. Mittermayer,, C. Nonhoff,, K. J. Oakton,, F. Praplan,, H. Ramos,, G. C. Schito,, J. Van Eldere,, J. Verhaegen,, J. Verhoef,, and M. R. Visser. 2002. Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J. Antimicrob. Chemother. 49: 289– 300.
64. Livermore, D. M.,, T. G. Winstanley,, and K. P. Shannon. 2001. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J. Antimicrob. Chemother. 47 (Suppl. 1): 87– 102.
65. Mazzariol, A.,, M. Aldegheri,, M. Ligozzi,, G. L. Cascio,, R. Koncan,, and R. Fontana. 2008. Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of b-lactam resistance. J. Clin. Microbiol. 46: 2095– 2098.
66. Medeiros, A. A.,, and J. Crellin. 2000. Evaluation of the Sirscan automated zone reader in a clinical microbiology laboratory. J. Clin. Microbiol. 38: 1688– 1693.
67. Munro, S.,, R. M. Mulder,, S. M. Farnham,, and B. Grinius,. 2004. Evaluating antimicrobial susceptibility test systems, p. 5.17.1– 5.17.9. In H. D. Isenberg (ed.), Clinical Microbiology Procedures Handbook, 2nd ed. ASM Press, Washington, DC.
68. Murdoch, D. R.,, S. Mirrett,, L. J. Harrell,, S. M. Donabedian,, M. J. Zervos,, and L. B. Reller. 2003. Comparison of MicroScan broth microdilution, synergy quad plate agar dilution, and disk diffusion screening methods for detection of high-level aminoglycoside resistance in Enterococcus species. J. Clin. Microbiol. 41: 2703– 2705.
69. Nakasone, I.,, T. Kinjo,, N. Yamane,, K. Kisanuki,, and C. M. Shiohira. 2007. Laboratory-based evaluation of the colorimetric VITEK-2 Compact system for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK-2 Compact system identification and antimicrobial susceptibility testing. Diagn. Microbiol. Infect. Dis. 58: 191– 198.
70. Nijs, A.,, R. Cartuyvels,, A. Mewis,, V. Peeters,, J. L. Rummens,, and K. Magerman. 2003. Comparison and evaluation of Osiris and Sirscan 2000 antimicrobial susceptibility systems in the clinical microbiology laboratory. J. Clin. Microbiol. 41: 3627– 3630.
71. Pfaller, M. A.,, and R. N. Jones. 2006. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med. 130: 767– 778.
72. Richter, S. S.,, W. J. Howard,, M. P. Weinstein,, D. A. Bruckner,, J. F. Hindler,, M. Saubolle,, and G. V. Doern. 2007. Multicenter evaluation of the BD Phoenix automated microbiology system for antimicrobial susceptibility testing of Streptococcus species. J. Clin. Microbiol. 45: 2863– 2871.
73. Roisin, S.,, C. Nonhoff,, O. Denis,, and M. J. Struelens. 2008. Evaluation of new VITEK 2 card and disk diffusion method for determining susceptibility of Staphylococcus aureus to oxacillin. J. Clin. Microbiol. 46: 2525– 2528.
74. Rolain, J. M.,, M. N. Mallet,, P. E. Fournier,, and D. Raoult. 2004. Real-time PCR for universal antibiotic susceptibility testing. J. Antimicrob. Chemother. 54: 538– 541.
75. Rosenberg, J.,, F. C. Tenover,, J. Wong,, W. Jarvis,, and D. J. Vugia. 1997. Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci? J. Clin. Microbiol. 35: 2526– 2530.
76. Sader, H. S.,, T. R. Fritsche,, and R. N. Jones. 2006. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J. Clin. Microbiol. 44: 1101– 1104.
77. Sakoulas, G.,, H. S. Gold,, L. Venkataraman,, P. C. Degirolami,, G. M. Eliopoulos,, and Q. Qian. 2001. Methicillin- resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J. Clin. Microbiol. 39: 3946– 3951.
78. Sanchez, M. A.,, B. Sanchez del Saz,, E. Loza,, F. Baquero,, and R. Canton. 2001. Evaluation of the OSIRIS video reader for disk diffusion susceptibility test reading. Clin. Microbiol. Infect. 7: 352– 357.
79. Sanders, C. C.,, M. Peyret,, E. S. Moland,, C. Shubert,, K. S. Thomson,, J.-M. Boeufgras,, and W. E. Sanders. 2000. Ability of the VITEK 2 Advanced Expert System to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 38: 570– 574.
80. Sanders, C. C.,, M. Peyret,, E. S. Moland,, S. J. Cavalieri,, C. Shubert,, K. S. Thomson,, J.-M. Boeufgras,, and W. E. Sanders. 2001. Potential impact of the VITEK 2 System and the Advanced Expert System on the clinical laboratory of a university-based hospital. J. Clin. Microbiol. 39: 2379– 2385.
81. Sanguinetti, M.,, B. Posteraro,, T. Spanu,, D. Ciccaglione,, L. Romano,, B. Fiori,, G. Nicoletti,, S. Zanetti,, and G. Fadda. 2003. Characterization of clinical isolates of Enterobacteriaceae from Italy by the Phoenix extended-spectrum β-lactamase detection method. J. Clin. Microbiol. 41: 1463– 1468.
82. Sorlozano, A.,, J. Gutierrez,, G. Piedrola,, and M. J. Soto. 2005. Acceptable performance of VITEK 2 system to detect extended-spectrum b-lactamases in clinical isolates of Escherichia coli: a comparative study of phenotypic commercial methods and NCCLS guidelines. Diagn. Microbiol. Infect. Dis. 51: 191– 193.
83. Spanu, T.,, M. Sanguinetti,, M. Tumbarello,, T. D’Inzeo,, B. Fiori,, B. Posteraro,, R. Santangelo,, R. Cauda,, and G. Fadda. 2006. Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates . J. Clin. Microbiol. 44: 3257– 3262.
84. Spanu, T.,, M. Sanguinetti,, T. D’Inzeo,, D. Ciccaglione,, L. Romano,, F. Leone, P Mazzella, and G. Fadda. 2004. Identification of methicillin-resistant isolates of Staphylococcus aureus and coagulase-negative staphylococci responsible for bloodstream infections with the Phoenix™ system. Diagn. Microbiol. Infect. Dis. 48: 221– 227.
85. Stefaniuk, E.,, A. Baraniak,, M. Gniadkowski,, and W. Hryniewicz. 2003. Evaluation of the BD Phoenix automated identification and susceptibility testing system in clinical microbiology laboratory practice. Eur. J. Clin. Microbiol. Infect. Dis. 22: 479– 485.
86. Steward, C. D.,, J. M. Mohammed,, J. M. Swenson,, S. A. Stocker,, P. P. Williams,, R. P. Gaynes,, J. E. McGowan,, and F. C. Tenover. 2003. Antimicrobial susceptibility testing of carbapenems: multicenter validity and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J. Clin. Microbiol. 41: 351– 358.
87. Sturenburg, E.,, I. Sobottka,, H.-H. Feucht,, D. Mack,, and R. Laufs. 2003. Comparison of BD Phoenix and VITEK 2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagn. Microbiol. Infect. Dis. 45: 29– 34.
88. Sturenburg, E.,, M. Lang,, M. A. Horstkotte,, R. Laufs,, and D. Mack. 2004. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum β-lactamases in clinical isolates of oxyimino-cephalosporinresistant gram-negative bacteria . J. Antimicrob. Chemother. 54: 870– 875.
89. Swenson, J. M.,, D. Lonsway,, S. McAllister,, A. Thompson,, L. Jevitt,, W. Zhu,, and J. B. Patel. 2007. Detection of mecAmediated resistance using reference and commercial testing methods in a collection of Staphylococcus aureus expressing borderline oxacillin MICs. Diagn. Microbiol. Infect. Dis. 58: 33– 39.
90. Swenson, J. M.,, K. F. Anderson,, D. R. Lonsway,, A. Thompson,, S. K. McAllister,, B. M. Limbago,, R. B. Carey,, F. C. Tenover,, and J. B. Patel. 2009. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J. Clin. Microbiol. 47: 2013– 2017.
91. Tenover, F. C.,, J. M. Swensen,, C. M. O’Hara,, and S. A. Stocker. 1995. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J. Clin. Microbiol. 33: 1524– 1527.
92. Tenover, F. C.,, L. M. Weigel,, P. C. Appelbaum,, L. K. McDougal,, J. Chaitram,, S. McAllister,, N. Clark,, G. Killgore,, C. M. O’Hara,, L. Jevitt,, J. B. Patel,, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48: 275– 280.
93. Tenover, F. C.,, M. V. Lancaster,, B. C. Hill,, C. D. Steward,, S. A. Stocker,, G. A. Hancock,, C. M. O’Hara,, N. C. Clark,, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36: 1020– 1027.
94. Tenover, F. C.,, P. P. Williams,, S. Stocker,, A. Thompson,, L. A. Clark,, B. Limbago,, R. B. Carey,, S. M. Poppe,, D. Shinabarger,, and J. E. McGowan. 2007. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45: 2917– 2922.
95. Tenover, F. C.,, R. K. Kalsi,, P. P. Williams,, R. C. Carey,, S. Stocker,, D. Lonsway,, J. K. Rasheed,, J. W. Biddle,, J. E. McGowan,, and B. Hanna. 2006. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing . Emerg. Infect. Dis. 12: 1209– 1213.
96. Thomson, K. S.,, N. E. Cornish,, S. G. Hong,, K. Hemrick,, C. Herdt,, and E. S. Moland. 2007. Comparison of Phoenix and VITEK 2 extended-spectrum-β-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized b-lactamases. J. Clin. Microbiol. 45: 2380– 2384.
97. Tsakris, A.,, A. Pantazi,, S. Pournaras,, A. Maniatis,, A. Polyzou,, and D. Sofianou. 2000. Pseudo-outbreak of imipenem-resistant Acinetobacter baumannii resulting from false susceptibility testing by a rapid automated system. J. Clin. Microbiol. 38: 3505– 3507.
98. Turnidge, J. D.,, and J. M. Bell,. 2005. Antimicrobial susceptibility on solid media, p. 8– 60. In V. Lorin (ed.), Antibiotics in Laboratory Medicine, 5th ed. The Williams & Wilkins Co., Baltimore, MD.
99. Van Den Braak, N.,, W. Goessens,, A. van Belkum,, H. A. Verbrugh,, and H. P. Endtz. 2001. Accuracy of the VITEK 2 system to detect glycopeptide resistance in enterococci. J. Clin. Microbiol. 39: 351– 353.
100. Weissmann, D.,, J. Spargo,, C. Wennersten,, and M. J. Ferrarro. 1991. Detection of enterococcal high-level aminoglycoside resistance with MicroScan freeze-dried panels containing newly modified medium and VITEK gram-positive susceptibility cards. J. Clin. Microbiol. 29: 1232– 1235.
101. White, R. L.,, M. B. Kays,, L. V. Friedrich,, E. W. Brown,, and J. R. Koonce. 1991. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels . J. Clin. Microbiol. 29: 398– 400.
102. Winstanley, T. G.,, H. K. Parsons,, M. A. Horstkotte,, I. Sobottka,, and E. Sturenburg. 2005. Phenotypic detection of β-lactamase-mediated resistance to oxyimino-cephalosporins in Enterobacteriaceae: evaluation of the Mastacan Elite Expert System. J. Antimicrob. Chemother. 56: 292– 296.
103. Woods, G. L.,, B. DiGiovanni,, M. Levison,, P. Pitsakis,, and D. LaTemple. 1993. Evaluation of MicroScan rapid panels for detection of high-level aminoglycoside resistance in enterococci. J. Clin. Microbiol. 31: 2786– 2787.
a Bio-Rad, Hercules, CA, http://bio-rad.com; i2a, Montpellier, France; Mast, Bootle, United Kingdom, http://www.mastascan.com; Oxoid, Basingstoke, United Kingdom, http://www.oxoid.com. See text for other manufacturers.
b Not currently available within the United States.
a neg, negative; ON, overnight; pos, positive; RUO, research use only.
a Resistance phenotypes that are rare or have not yet been detected may represent technical errors.
a Implementation of the revised (2010) cephalosporin and aztreonam CLSI breakpoints for Enterobacteriaceae makes routine ESBL testing unnecessary unless there is consideration of using the agents listed. If ESBL testing is performed and results are positive, the organisms should be reported as resistant to these drugs.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.